Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-214190 · Präparat HOS-155288
Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives
(ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone)
were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin
and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral
contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) estradiol (HOS-090751) digoxin (HOS-086172) luteinizing hormone (HOS-090752) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage c221258196c425ba365f2badbf8ae5202296c376935ecb5c2c3aec58df95213c · Zeichen 1767–2226 im Abschnitt
Wechselwirkungen · Levetiracetam Actavis Group
Levetiracetam Actavis Group 100 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-125192 · Präparat HOS-096021
Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-
estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not
modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin and
warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives
and warfarin did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) estradiol (HOS-090751) digoxin (HOS-086172) luteinizing hormone (HOS-090752) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T13:19:00Z · SHA-256 922445385f872a12bb2cbb8705a2e36092efd96aae1726df5bc6e965246270d2 · Passage e1e51368ad7d29c7acd59a755d7b3a47faeba11830a4ac3ac432c2676c662ce5 · Zeichen 1713–2173 im Abschnitt
Wechselwirkungen · Levetiracetam Teva
Levetiracetam Teva 250 mg film-coated tablets Levetiracetam Teva 500 mg film-coated tablets Levetiracetam Teva 750 mg film-coated tablets Levetiracetam Teva 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-214464 · Präparat HOS-155334
Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives
(ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone)
were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin
and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral
contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) digoxin (HOS-086172) luteinizing hormone (HOS-090752) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:57:00Z · SHA-256 00c2f434cd2af751cf182e14e81590dcb66cb2d00e251e330133d26672f07777 · Passage b2dfe9679d733680f1c59df5098bed41f0571f686251188f5a35c1031ffb67a0 · Zeichen 1767–2225 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-215319 · Präparat HOS-155418
Efavirenz: no clinically significant
interaction.
The clinical significance of these
effects is not known.
Injection: In a 3-month drug interaction study, Because of the limited
Depomedroxyprogesterone no significant differences in MPA information available, a reliable
acetate (DMPA)/efavirenz pharmacokinetic parameters were method of barrier contraception
(150 mg IM single dose DMPA) found between subjects receiving must be used in addition to
efavirenz-containing antiretroviral hormonal contraceptives (see
therapy and subjects receiving no section 4.6).
antiretroviral therapy. Similar results
were found by other investigators,
although the MPA plasma levels were
more variable in the second study. In
both studies, plasma progesterone
levels for subjects receiving efavirenz
and DMPA remained low consistent
with suppression of ovulation.
Implant: Etonogestrel/efavirenz Decreased exposure of etonogestrel A reliable method of barrier
may be expected (CYP3A4 contraception must be used in
induction). There have been addition to hormonal
occasional postmarketing reports of contraceptives (see section 4.6).
contraceptive failure with
etonogestrel in efavirenz-exposed
patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) acetate (HOS-088133) etonogestrel (HOS-144596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 8952614af172de542468d8f04a229b11865e1da72dd9cff88f789d1c400a8a34 · Zeichen 55262–57260 im Abschnitt
Wechselwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-215371 · Präparat HOS-155426
Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives
(ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone)
were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin
and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral
contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) digoxin (HOS-086172) luteinizing hormone (HOS-090752) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage b2dfe9679d733680f1c59df5098bed41f0571f686251188f5a35c1031ffb67a0 · Zeichen 1769–2227 im Abschnitt
Wechselwirkungen · Kalydeco
Kalydeco 75 mg film-coated tablets Kalydeco 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-126448 · Präparat HOS-096263
Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no
significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral
contraceptives is necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-02T15:40:00Z · SHA-256 3213de37cc075be5d4409b79807f1ec8017896be60e7edb796dfbe660a1e4b9f · Passage 6d5e43f985a3e9baa1ed7c05b0947bbce2e23f5d99bd34999d4cd90635725780 · Zeichen 4204–4435 im Abschnitt
Wechselwirkungen · Kalydeco
Kalydeco 13.4 mg granules in sachet Kalydeco 25 mg granules in sachet Kalydeco 50 mg granules in sachet Kalydeco 59.5 mg granules in sachet Kalydeco 75 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 42
HOS-126515 · Präparat HOS-096263
Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no
significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral
contraceptives is necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-02T15:40:00Z · SHA-256 3213de37cc075be5d4409b79807f1ec8017896be60e7edb796dfbe660a1e4b9f · Passage 6d5e43f985a3e9baa1ed7c05b0947bbce2e23f5d99bd34999d4cd90635725780 · Zeichen 4284–4515 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-129167 · Präparat HOS-096689
10
(induction of UGT1A1 and
CYP3A enzymes)
Oral contraceptives
Ethinyl estradiol (EE) Dolutegravir Dolutegravir had no pharmacodynamic effect on
and Norelgestromin EE Luteinizing Hormone (LH), Follicle Stimulating
(NGMN) AUC 3% Hormone (FSH) and progesterone. No dose
Cmax 1% adjustment of oral contraceptives is necessary
when co-administered with dolutegravir.
NGMN
AUC 2%
Cmax 11%
Analgesics
Methadone Dolutegravir No dose adjustment is necessary of either agent.
Methadone
AUC 2%
Cmax 0%
C 1%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) methadone (HOS-086198) norelgestromin (HOS-110295) ethinyl estradiol (HOS-088135) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage 2725539b2dc323f148c972f568fece3798f1ba5105fb22e3d9d7896ebd0480da · Zeichen 17501–18499 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 40–41
HOS-129202 · Präparat HOS-096689
40
Ethinyl estradiol (EE) Dolutegravir Dolutegravir had no pharmacodynamic effect on
and Norelgestromin EE Luteinizing Hormone (LH), Follicle Stimulating
(NGMN) AUC 3% Hormone (FSH) and progesterone. No dose
Cmax 1% adjustment of oral contraceptives is necessary
when co-administered with dolutegravir.
NGMN
AUC 2%
Cmax 11%
Analgesics
Methadone Dolutegravir No dose adjustment is necessary of either agent.
Methadone
AUC 2%
Cmax 0%
C 1%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) methadone (HOS-086198) norelgestromin (HOS-110295) ethinyl estradiol (HOS-088135) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage 273d707acca69f72ccf12205541e05fde735dd8f8197963f7e7ffa28c479f567 · Zeichen 17876–18761 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-129279 · Präparat HOS-096703
14
available for this dose adjustment, see
section 4.2).
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) ethinyl estradiol (HOS-088135) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 43410c94b6dbbc0219581d49891490b32c1f5a61b551a7d4fe3c782cf1266f3e · Zeichen 29393–31452 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50–52
HOS-129364 · Präparat HOS-096703
50
(Complex binding to The stated reductions in dolutegravir
polyvalent ions) exposure were observed with the intake
Multivitamins (containing Dolutegravir ↓ of dolutegravir and these supplements
calcium, iron and magnesium) AUC ↓ 33% during fasted conditions. In fed state, the
/Dolutegravir Cmax ↓ 35% changes in exposure following intake
C24 ↓ 32% together with calcium or iron
supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease should be adjusted when co-
expected due to induction administered with St. John’s wort.
of UGT1A1 and CYP3A
enzymes, a similar Dosing recommendations are provided
reduction in exposure as in Table 2 (see section 4.2)
observed with
carbamazepine is
expected)
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
51
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 4f0d85e516680fd44841c8a2084bad237df81c83647e075fbfa5f388b51c50c4 · Zeichen 22392–27416 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg film-coated tablets Briviact 25 mg film-coated tablets Briviact 50 mg film-coated tablets Briviact 75 mg film-coated tablets Briviact 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132738 · Präparat HOS-097290
Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol
(0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance.
When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum
daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel
(0.15 mg), a reduction in oestrogen and progestin AUCs of 27 % and 23 %, respectively, was observed
without impact on suppression of ovulation. There was generally no change in the concentration-time
profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle
stimulating hormone (FSH), and sex hormone binding globulin (SHBG).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) estradiol (HOS-090751) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage 377b0501e38f94634dc5563fc64ec127efbaa1f9504cd5ee878f8c609fff254c · Zeichen 6895–7646 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 28
HOS-132774 · Präparat HOS-097290
Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol
(0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance.
When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum
daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel
(0.15 mg), a reduction in oestrogen and progestin AUCs of 27 % and 23 %, respectively, was observed
without impact on suppression of ovulation. There was generally no change in the concentration-time
profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle
stimulating hormone (FSH), and sex hormone binding globulin (SHBG).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) estradiol (HOS-090751) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage 377b0501e38f94634dc5563fc64ec127efbaa1f9504cd5ee878f8c609fff254c · Zeichen 6987–7738 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml solution for injection/infusion · Abschnitt 4.5 · PDF-Seite 44
HOS-132810 · Präparat HOS-097290
Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol
(0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance.
When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum
daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel
(0.15 mg), a reduction in oestrogen and progestin AUCs of 27 % and 23 %, respectively, was observed
without impact on suppression of ovulation. There was generally no change in the concentration-time
profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle
stimulating hormone (FSH), and sex hormone binding globulin (SHBG).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) levonorgestrel (HOS-089677) estradiol (HOS-090751) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage 377b0501e38f94634dc5563fc64ec127efbaa1f9504cd5ee878f8c609fff254c · Zeichen 6982–7733 im Abschnitt
Wechselwirkungen · Symkevi
Symkevi 50 mg/75 mg film-coated tablets Symkevi 100 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-140706 · Präparat HOS-098562
Symkevi in combination with ivacaftor has been studied with an estrogen/progesterone oral
contraceptive and was found to have no significant effect on the exposures of the hormonal
contraceptive. Symkevi and ivacaftor are not expected to modify the efficacy of hormonal
contraceptives.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-08T13:35:00Z · SHA-256 e139cc35dca65a70a96b9c8a1ad8e556657e48aee661616c1f43437d6b315911 · Passage cbdeac995882cbd3264753f3f71d32f3741a01093a3df72984a33674379afcf3 · Zeichen 4685–4970 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-142843 · Präparat HOS-098886
11
Multivitamins (containing Dolutegravir during fasted conditions. In fed state, the
calcium, iron and magnesium) AUC 33% changes in exposure following intake
/Dolutegravir Cmax 35% together with calcium or iron
(fasted intake) C24 32% supplements were modified by the food
(Complex binding to effect, resulting in an exposure similar to
polyvalent ions) that obtained with dolutegravir
administered in the fasted state.
Proton pump inhibitors
Omeprazole Dolutegravir No dosage adjustment necessary.
Corticosteroids
Prednisone/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin/Dolutegravir Metformin A dose adjustment of metformin should
Dolutegravir be considered when starting and
When co-administered stopping coadministration of Dovato
with dolutegravir 50 mg with metformin, to maintain glycaemic
QD: control. In patients with moderate renal
Metformin impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with Dovato, because of
When co-administered the increased risk for lactic acidosis in
with dolutegravir 50 mg patients with moderate renal impairment
BID: due to increased metformin
Metformin concentration (section 4.4).
AUC 145 %
Cmax 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, decrease is 50 mg twice daily when co-
expected due to induction administered with St. John’s wort. As
of UGT1A1 and CYP3A Dovato is a fixed-dose tablet, an
enzymes, a similar additional 50 mg tablet of dolutegravir
reduction in exposure as should be administered, approximately
observed with 12 hours after Dovato for the duration of
carbamazepine is the St. John’s wort co-administration (a
expected). separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no pharmacodynamic
Norgestromin EE effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC 3% Follicle Stimulating Hormone (FSH) and
Cmax 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Dovato.
NGMN
AUC 2%
Cmax 11%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 2f6766181d55d8513097e83ade1239e25819402a3fdabb28f23368f6b03130e3 · Zeichen 23358–27625 im Abschnitt
Wechselwirkungen · Sugammadex Mylan
Sugammadex Mylan 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-147231 · Präparat HOS-099618
Interference with laboratory tests:
In general sugammadex does not interfere with laboratory tests, with the possible exception of the
serum progesterone assay. Interference with this test is observed at sugammadex plasma
concentrations of 100 microgram/mL (peak plasma level following 8 mg/kg bolus injection).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T12:10:00Z · SHA-256 9ec1fa705f8e9561364d6939c5b49bb94f7eaebcdb6bd4941da3eaf970e2490b · Passage 7a42ebd5239bd7bf93e2747a73434eaf0ad45b06f058d5028c25e99e12d918b5 · Zeichen 4514–4825 im Abschnitt
Wechselwirkungen · Sugammadex Fresenius Kabi
Sugammadex Fresenius Kabi100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-149285 · Präparat HOS-100028
In general sugammadex does not interfere with laboratory tests, with the possible exception of the
serum progesterone assay. Interference with this test is observed at sugammadex plasma concentrations
of 100 microgram/mL (peak plasma level following 8 mg/kg bolus injection).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T10:40:00Z · SHA-256 79ed2617c03021938f3c30d4a96235d103e6906eb41d5296fcbeabec10b1a667 · Passage f028e312f2ed503edc77f0c594e90efd4664729c56f95d7009c7decf671df649 · Zeichen 4593–4868 im Abschnitt
Wechselwirkungen · Sugammadex Adroiq
Sugammadex Adroiq 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 8
HOS-150956 · Präparat HOS-100426
In general sugammadex does not interfere with laboratory tests, with the possible exception of the
serum progesterone assay. Interference with this test is observed at sugammadex plasma
concentrations of 100 microgram/mL (peak plasma level following 8 mg/kg bolus injection).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:21:00Z · SHA-256 e7be1eb58d32faccb389767c0e9e5884057016dec53c72705ce1121f897cfb97 · Passage a69ccb8f368fb803f4d6962d97f71d94e15309ba78375389a24b145f4514baa1 · Zeichen 4633–4908 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.